# Efgartigimod in IVIG Dependent Myasthenia Gravis Patients

> **NCT06765161** · PHASE3 · RECRUITING · sponsor: **Clinique Neuro-Outaouais** · enrollment: 30 (estimated)

## Conditions studied

- Myasthaenia Gravis

## Interventions

- **DRUG:** efgartigimod administration

## Key facts

- **NCT ID:** NCT06765161
- **Lead sponsor:** Clinique Neuro-Outaouais
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-06
- **Primary completion:** 2027-01-06
- **Final completion:** 2027-01-06
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06765161

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06765161, "Efgartigimod in IVIG Dependent Myasthenia Gravis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06765161. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*